돌아가기
Huagongshe화공사 화학 정보 인쇄 보고서 · 연구 참고용
HRID 332933생성일: 2026년 10월 24일

Dimethylformamide → Lenalidomide

https://huagongshe.com/ko/reaction/332933

반응식

참여 물질

역할이름HCID투입량
반응물DimethylformamideHCID 6228—
반응물3-(4-Nitro-1-oxo-1,3-dihydroisoindol-2-yl)piperidine-2,6-dioneHCID 11471781—
용매EthanolHCID 702—
용매MethanolHCID 887—
용매IsopropanolHCID 3776—
생성물LenalidomideHCID 216326—
생성물3-(4-Nitro-1-oxo-1,3-dihydroisoindol-2-yl)piperidine-2,6-dioneHCID 11471781—

반응 단계

By catalytic hydrogenation of 3-(4-nitro-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione in solvents such as dimethylformamide, methanol, ethanol, isopropyl alcohol or mixture of these solvents at temperature 50-100.0° C. under pressure or bubbling of hydrogen gas at atmospheric pressure, then filteration of the catalyst followed by distillation under high vacuum Lenalidomide polymorphic form-I is obtained. The polymorphic form-I of Lenalidomide can also be obtained by transfer hydrogenation of 3-(4-nitro-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione using solvents dimethylformamide, methanol, ethanol, isopropyl alcohol or mixture of these solvents at temperature 50-100.0° C. using ammonium formate or formic acid as source of hydrogen. The precious metal catalysts used in the hydrogenation are Raney Nickel, palladium etc., followed by filteration of catalyst and distillation of the solvent under high vacuum.

출처 및 근거

DOI10.6084/m9.figshare.5104873.v1
특허 번호US08877932B2
출처 데이터셋uspto-grants-2014_11
ORD IDord-3b1e366387a14741897b3bf6a17c7df5
출처 메모uspto-grants-2014_11